<SEC-DOCUMENT>0001213900-22-056257.txt : 20230119
<SEC-HEADER>0001213900-22-056257.hdr.sgml : 20230119
<ACCEPTANCE-DATETIME>20220915163826
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-22-056257
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			China Jo-Jo Drugstores Holdings, Inc.
		CENTRAL INDEX KEY:			0001856084
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		HAI WAI HAI TONGXIN MANSION FLOOR 6
		STREET 2:		GONG SHU DISTRICT
		CITY:			HANGZHOU CITY
		STATE:			F4
		ZIP:			310008
		BUSINESS PHONE:		8657188219579

	MAIL ADDRESS:	
		STREET 1:		HAI WAI HAI TONGXIN MANSION FLOOR 6
		STREET 2:		GONG SHU DISTRICT
		CITY:			HANGZHOU CITY
		STATE:			F4
		ZIP:			310008
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">China Jo-Jo Drugstores Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Hai Wai Hai Tongxin Mansion Floor 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Gong Shu District, Hangzhou City, Zhejiang Province</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">People&rsquo;s Republic of China, 310008</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">September 15, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>VIA EDGAR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Office of Trade &amp; Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">100 F Street, N.E</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Washington, DC 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Brian Fetterolf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>China Jo-Jo Drugstores Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Amended Registration Statement on Form F-3</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Filed August 5, 2022</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>File No. 333-259692</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Fetterolf:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter is being furnished
in response to the comments of the staff (the &ldquo;Staff&rdquo;) of the Division of Corporation Finance of the Securities and Exchange
Commission (the &ldquo;Commission&rdquo;) that were contained in the Staff&rsquo;s letter dated August 30, 2022 (the &ldquo;Comment Letter&rdquo;),
to China Jo-Jo Drugstores Inc. (the &ldquo;Company&rdquo;) with respect to the Amendment No. 2 to Registration Statement on Form F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter provides the Company&rsquo;s
responses to the Staff&rsquo;s comments contained in the Comment Letter. The text of the Staff&rsquo;s comments is set forth in bold below,
followed by the responses of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.25in 0pt 0; text-align: justify"><B><U>Amendment No. 2 to Registration
Statement on Form S-3 [sic] filed August 5, 2022 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.25in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.25in 0pt 0; text-align: justify"><B><U>Cover Page</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.25in 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>We note your response to comment 1, as well as your amended disclosure that &ldquo;[w]e, through contractual
agreements, establish the VIE structure <U>to manage and invest</U> Chinese-based companies . . . .&rdquo; Please revise to state that
you, through contractual agreements, establish the VIE structure <U>to provide exposure to foreign investment</U> in such China-based
companies, as you state on page 2. Also revise your disclosure on page 10 that &ldquo;[t]he VIE structure is used <U>in</U> foreign investment
in Chinese-based companies . . . &rdquo; to similarly disclose that such structure is used <U>to provide exposure</U> to foreign investment
in such companies. (Emphasis added with respect to all quoted language.)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised its disclosure as requested in the Amendment No. 3 to the Registration Statement on Form
F-3 (&ldquo;Amended F-3&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD STYLE="text-align: justify"><B>We note your response to comment 2, as well as your disclosure that &ldquo;[a]ll references to &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;the Company,&rdquo; &ldquo;CJJD,&rdquo; or similar terms used in this prospectus refer to
China Jo-Jo Drugstores, Inc., a Cayman Islands exempted company with limited liability, including its consolidated subsidiaries, <U>the
variable interest entities (&ldquo;VIEs&rdquo;) and the VIEs&rsquo; subsidiaries</U>, unless the context otherwise indicates&rdquo; (emphasis
added). Please remove the references to the VIEs and their subsidiaries from this definition of the registrant, disclose how you will
refer to the VIEs and their subsidiaries when providing disclosure throughout the document so that it is clear to investors which entities
the disclosure is referencing, and revise the prospectus accordingly. Make conforming changes on page 1 in your prospectus summary. Also
revise the second sentence of the 10th paragraph of the cover page, as well as the first paragraph of &ldquo;Overview&rdquo; on page 2,
to identify &ldquo;[y]our entity&rdquo; that is offering the securities in this offering.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised its disclosure to clearly indicate the entities in the designated places and throughout
the Amended F-3.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Please disclose whether your auditor is subject to the determinations announced by the PCAOB on December
16, 2021 and whether and how the Holding Foreign Companies Accountable Act, the Accelerating HFCAA and related regulations will or would
affect your company. Include a reference to the agreement reached by the PCAOB and PRC authorities on August 26, 2022. Make conforming
changes in your discussion on page 12 in the section entitled &ldquo;Cautionary Statement Regarding Holding Foreign Companies Accountable
Act&rdquo; and in your risk factors.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised its disclosure on the cover page, in the section entitled &ldquo;Cautionary Statement Regarding
Holding Foreign Companies Accountable Act&rdquo; and risk factors named &ldquo;<I>Our auditor is headquartered in Irvine, California, and
is subject to inspection by the PCAOB on a regular basis. To the extent that our independent registered public accounting firm&rsquo;s
audit documentation related to their audit reports for our company become located in China, the PCAOB may not be able to inspect such
audit documentation and, as such, you may be deprived of the benefits of such inspection and our ordinary shares could be delisted from
the stock exchange pursuant to the Holding Foreign Companies Accountable Act&rdquo;</I> in the Amended F-3.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD STYLE="text-align: justify"><B>We note your cross-reference to your general &ldquo;Risk Factors&rdquo; section. Please also include
a cross-reference to the sub-section entitled &ldquo;Risks Related to Our Corporate Structure and Doing Business in the PRC&rdquo; beginning
on page 13. Please revise the first sentence of the 11th paragraph of the cover page to state that the risks being discussed also could
result in the value of your securities to significantly decline or be worthless.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has included the reference to China-related risks and has added one sentence as requested on the cover
page of the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD STYLE="text-align: justify"><B>We note your response to comment 4. In connection therewith:</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>We note your disclosure that &ldquo;[a]s of the date of this prospectus, the Company did not have any
distributions and does not intend to distribute any dividends in any forms in the near future.&rdquo; Please also disclose whether any
dividends or distributions have been made to your investors, whether through your holding company, subsidiaries or consolidated VIEs,
quantify such amounts, and make conforming changes on page 8.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>Revise your disclosure discussing transfers between Jiuxin Medicine to Jiuzhou Pharmacy to quantify
the amounts in the last three fiscal years, as you do on page 8. Ensure your discussion here discloses your intentions to distribute earnings
or settle amounts owed under all of the VIE agreements and revise page 8 accordingly, and in addition to the transfers between Jiuxin
Medicine to Jiuzhou Pharmacy, disclose whether any other transfers have been made between the holding company, its subsidiaries and the
other consolidated VIEs and quantify as applicable. In particular, state whether there have been any transfers involving the other VIEs,
and make conforming changes on page 8 where you similarly only discuss the two VIEs Jiuxin Medicine and Jiuzhou Pharmacy.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>Provide cross-references to the condensed consolidating schedule and the consolidated financial statements
on the cover page and in your summary in the section entitled &ldquo;Cash Transfer and Dividend Payment.&rdquo;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has 1) clearly laid out the distribution history on the cover page and on page 8; 2) added disclosure
regarding the transfer amounts between Jiuxin Medicine to Jiuzhou Pharmacy in the last three fiscal years on the cover page; 3) added
disclosure regarding the transfers between our subsidiary and VIEs, and the transfers between the VIEs in the last three fiscal years
on the cover page and in the section entitled &ldquo;<I>Cash Transfer and Dividend Payment</I>&rdquo;; and 4) provided cross-references
to the condensed consolidating schedule and the consolidated financial statements on the cover page and in our summary in the section
entitled &ldquo;<I>Cash Transfer and Dividend Payment</I>&rdquo; as requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Please amend your disclosure here and in the summary, summary risk factors and risk factors sections
to state that, to the extent cash or assets in the business is in the PRC/Hong Kong or a PRC/Hong Kong entity, the funds or assets may
not be available to fund operations or for other use outside of the PRC/Hong Kong due to interventions in or the imposition of restrictions
and limitations on the ability of you, your subsidiaries, or the consolidated VIEs by the PRC government to transfer cash or assets. On
the cover page, provide cross-references to these other discussions.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has added such statement on the cover page, in the prospectus summary, summary of risk factors, and
risk factors of the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>7.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure on page 8 that discusses some of your cash management policies, such as regulatory
limitations on your ability to transfer cash between you, your subsidiaries or investors. Please briefly discuss such limitations here
and provide a cross-reference to your discussion of this issue in your summary. In both places, describe any other regulatory cash management
policies that dictate how funds are transferred, as well as any such policies that are contractual in nature, and identify which regulations/contracts
dictate which policies.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response:</B> The Company has made
the cross-reference to its discussion of the regulatory limitations related to the cash transfer in on the cover page. Other than the
Company&rsquo;s cash management policy disclosed on page 9 of the Amended F-3, the Company does not have any applicable regulatory or
contractual cash management policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure that &ldquo;<U>holding</U> the Company through contractual agreements may not
be as effective as direct equity ownership . . . &rdquo; (emphasis added). Please explain what you mean by &ldquo;holding&rdquo; or revise
to clarify, if true, that you are &ldquo;conducting the operations&rdquo; of your company through contractual arrangements with the VIEs.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised the cover page of the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Prospectus Summary, page 1 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>9.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure on your cover page that there are four consolidated VIEs (Jiuzhou Pharmacy,
Jiuxin Medicine, Jiuzhou Service and Jiuzhou Clinic), but you do not highlight Linjia Medical as a VIE despite identifying such entity
as a VIE in your chart on page 5. Further, your structure chart indicates that Jiuxin Medicine is a wholly-owned subsidiary of Jiuzhou
Pharmacy, one of the VIEs, and also indicates that Linja <I>[sic]</I> Medical is a majority-owned subsidiary of Jiuzhou Pharmacy. Please
revise to clarify on the cover page and in your structure chart whether you consider Jiuxin Medicine and Linja <I>[sic]</I> Medical to
both be VIEs or to be solely operating subsidiaries of the VIEs, and provide us with your analysis as to why such entities are deemed
to be VIEs or not. To the extent that such entities are VIEs, revise your structure chart to indicate as such with dotted lines, revise
your cover page to ensure consistency, and also describe the related contractual arrangements with Jiuxin Medicine and Linja <I>[sic]</I>
Medical in your discussion of the VIEs&rsquo; contractual arrangements on pages 9 and 10.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company respectfully points out that Jiuxin Medicine and Linjia Medical are respectively a wholly-owned subsidiary
and a majority-owned subsidiary (as opposed to be the VIEs) of Jiuzhou Pharmacy. Although Jiuzhou Pharmacy is one of the VIEs, the connection
between Jiuxin Medicine and Jiuzhou Pharmacy as well as Linjia Medical and Jiuzhou Pharmacy shall not be dotted lines because they are
not VIEs&rsquo; VIEs. They are VIEs&rsquo; subsidiaries with equity ownerships. Readers could tell their overall relationship with the
holding companies by retrieving the dotted lines at the upper level in those between Jiuzhou Pharmacy and Jiuxin Management. In addition,
to avoid confusion, we have revised the table summarizing the status of the PRC Operating Entities under section &ldquo;<I>Our Current
Corporate Structure</I>&rdquo; in the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.</B></TD><TD STYLE="text-align: justify"><B>We note your response to comment 7, as well as your amended disclosure on page 4 in the paragraph beginning
with &ldquo;The management understood that neither the Company, nor any of its subsidiaries, including the VIEs are currently required
to obtain approval from Chinese authorities . . . to list on U.S. exchanges or issue securities to foreign investors.&rdquo; In connection
therewith, please:</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>Revise to expand your discussion to cover both permissions and approvals in each instance in which
you refer to either only a permission or approval.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>In each instance in which you refer to permissions or approvals required &ldquo;to list on U.S. exchanges,&rdquo;
expand such discussion to also cover permissions or approvals required to offer the securities being registered to foreign investors.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>Expand your discussion to cover the permissions or approvals required to operate your business, as
you do in your amended disclosure on page 11.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>Describe the consequences to you and your investors if you, your subsidiaries, or the VIEs do not receive
or maintain any required permissions or approvals or mistakenly conclude that any required permissions or approvals are not required,
or applicable laws change and require you to obtain permissions or approvals in the future. In this regard, we note that your disclosure
on page 11 appears to be limited to permissions or approvals required by the CSRC. For additional guidance, please see the Division of
Corporation Finance&rsquo;s Sample Letter to China-Based Companies issued by the Staff in December 2021, and in particular sample comment
8.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>State affirmatively whether you have received all requisite permissions or approvals to operate your
business and conduct this offering to foreign investors.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised accordingly as requested on page 4 of the Prospectus Summary, and under section &ldquo;<I>Licenses
and Permits</I>&rdquo; and &ldquo;<I>Cautionary Statement Regarding Doing Business in China</I>&rdquo; of the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>11.</B></TD><TD STYLE="text-align: justify"><B>Throughout your prospectus as applicable, disclose whether you relied upon an opinion of counsel with
respect to your conclusions regarding whether you are required to obtain various permissions or approvals to conduct your operations and
offer securities to investors. In this regard, we note your disclosure regarding &ldquo;[y]our PRC counsel&rdquo; on page 18, however it
is not clear whether counsel provided you with an opinion and, if so, the scope of such opinion. If you did not rely upon an opinion of
counsel with respect to your conclusions regarding permissions and approvals to operate your business and to offer securities to investors,
state as much, explain why such an opinion was not obtained, and discuss how you came to the stated conclusions and the basis on which
you made such determinations. If you did rely on an opinion of counsel, name the counsel in your summary and risk factor, file their consent
as an exhibit to this registration statement, and revise to address your reliance on local counsel with respect to specific conclusions
(for example in your disclosure on page 4 in which you state, &ldquo;[b]ased on the above and our understanding of the Chinese laws and
regulations currently in effect as of the date of this prospectus, we are not required to submit an application to the CSRC or he CAC
for the approval of this offering and the listing and trading our securities on the Nasdaq&rdquo;).</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response</B>: In response to the
Staff&rsquo;s comment, the Company has revised its disclosure accordingly throughout the Amended F-3 to clearly identify the source of
the conclusion. In addition, the Company respectfully points out that while the conclusion regarding the permissions and approvals to
list overseas and to offer securities to investors is from the Company&rsquo;s PRC Counsel, the Company&rsquo;s conclusion regarding permissions
and approvals to operate its business is based on its management belief, since it is the obligation of the Company management to maintain
and update the licenses and permissions and the Company has its in-house local counsel and special administrative staff in charge of matters
specifically related to its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>12.</B></TD><TD STYLE="text-align: justify"><B>Please clarify in your definition of &ldquo;China&rdquo; that the legal and operational risks associated
with operating in China also apply to operations in Hong Kong. Revise your prospectus to discuss the regulations applicable to you, the
VIEs and subsidiaries in the regions in which you and they operate, such as Hong Kong.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised accordingly as requested in the prospectus summary of the Amended F-3. In addition, the
Company respectfully points out to Staff that all of the Company&rsquo;s business is in mainland China. Renovation, as a subsidiary of
the Company, is an intermediate holding company and has no business operations in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Contractual Arrangement with HJ Group and
the Key Personnel, page 9</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>13.</B></TD><TD STYLE="text-align: justify"><B>We note your response to comment 5, as well as your amended disclosure discussing your &ldquo;relationships
with HJ Group and the Key Personnel.&rdquo; Please revise to define and discuss which entities and/or individuals comprise HJ Group and
the Key Personnel, as your disclosure is not clear as to how these entities and/or individuals are connected to your corporate structure.
To the extent applicable, ensure consistency between your discussion of Key Personnel and your discussion of the shareholders of the VIEs
on page 10.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised its disclosure accordingly as requested in the prospectus summary of the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Licenses and Permits, page 9</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>14.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure that the Draft Rules Regarding Overseas Listing &ldquo;have a comment period
that expires on January 23, 2022.&rdquo; Please update this discussion to disclose that such comment period has expired, if true.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><B>Response:
</B>In response to the Staff&rsquo;s comment, the Company has revised its disclosure accordingly under Section &ldquo;<I>Licenses and
Permits</I>&rdquo; as requested in the Prospectus Summary of the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cautionary Statement Regarding our Variable
Interest Entity Structure, page 10</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>15.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure that you are subject to risks due to uncertainty of &ldquo;the validity and
enforcement of the VIE Agreements&rdquo; and that you are &ldquo;subject to the risks of uncertainty about any future actions of the PRC
government in this regard.&rdquo; Please also disclose that the contractual arrangements may be less effective than direct ownership due
to such risks and that the company may incur substantial costs to enforce the terms of the arrangements. Also discuss the challenges the
company may face enforcing these contractual agreements due to legal uncertainties and jurisdictional limits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><B>Response:
</B>In response to the Staff&rsquo;s comment, the Company has added a sentence to disclose that &ldquo;the contractual arrangements may
be less effective than direct ownership due to such risks and that the company may incur substantial costs to enforce the terms of the
arrangements&rdquo; under Section &ldquo;<I>Cautionary Statement Regarding our Variable Interest Entity Structure</I>&rdquo; in the Prospectus
Summary of the Amended F-3. In addition, the Company respectfully points out that challenges the Company may face enforcing these contractual
agreements due to legal uncertainties and jurisdictional limits have been clearly disclosed under such section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>16.</B></TD><TD STYLE="text-align: justify"><B>We note your response to comment 3, as well as your amended disclosure, and we reissue the comment
in-part. Please revise any references to control or benefits that accrue to you because of the VIEs so that such discussion is limited
to and clearly describes the conditions you met for consolidation of the VIE under U.S. GAAP. Your disclosure should clarify that, for
accounting purposes, you will be the primary beneficiary. In this regard, please revise or remove your reference to &ldquo;absolute control
rights&rdquo; as well as your disclosure that the &ldquo;VIE Agreements may not be effective in providing control over the VIEs&rdquo; (page
11), that you &ldquo;have entered into a series of agreements that provide us with substantial ability to control the VIEs&rdquo; (page
14), that you &ldquo;may lose control of [y]our consolidated VIEs&rdquo; (page 14) and your discussion regarding your &ldquo;control over
[y]our consolidates VIEs&rdquo; (page 15). We further note references throughout the prospectus to &ldquo;our VIEs,&rdquo; &ldquo;our subsidiaries
and consolidated VIEs,&rdquo; &ldquo;our operating VIEs&rdquo; and similar statement. Please refrain from using terms such as &ldquo;we&rdquo;
or &ldquo;our&rdquo; when describing activities or functions of VIEs; instead, disclose that your VIEs are consolidated for accounting purposes
with you as the beneficiary but are not entities in which you own equity or control.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised its disclosure accordingly throughout Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>17.</B></TD><TD STYLE="text-align: justify"><B>We also note your amended disclosure on the cover page that &ldquo;[t]hese contractual agreements have
not been tested in a court of law.&rdquo; Please revise to disclose as such in this section.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><B>Response:
</B>In response to the Staff&rsquo;s comment, the Company has added such sentence under Section &ldquo;<I>Cautionary Statement Regarding
our Variable Interest Entity Structure</I>&rdquo; as requested in the Prospectus Summary of the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>18.</B></TD><TD STYLE="text-align: justify"><B>We note your response to comment 8, as well as your amended disclosure that &ldquo;due to the novelty
of this regulation and lack of the official guidance, the <U>CSRC</U> may reach a different conclusion&rdquo; (emphasis added). Please
revise to explain why the <U>CSRC</U> may reach a different conclusion with respect to the application of the Measures of Cybersecurity
Review or revise to clarify that the applicable agency is the <U>CAC</U>, if true (emphasis added).</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><B>Response:
</B>In response to the Staff&rsquo;s comment, the Company has revised its disclosure accordingly under Section &ldquo;<I>Cautionary Statement
Regarding our Variable Interest Entity Structure</I>&rdquo; as requested in the Prospectus Summary of the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cautionary Statement Regarding Doing Business
in China, page 11</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>19.</B></TD><TD STYLE="text-align: justify"><B>We note your response to comment 6 and we reissue the comment in-part. In particular:</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>Please include a summary risk factors section in the prospectus summary, and for each China-related
summary risk factor, include a cross-reference to the relevant individual detailed risk factor.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>We note your disclosure that &ldquo;the PRC government initiated a series of regulatory actions and
statements to regulate business operations in China with little advance notice . . . .&rdquo; Please revise to also state that rules and
regulations in China <U>can</U> change quickly with little advance notice (emphasis added).</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>Revise your disclosure that the &ldquo;PRC government may at any time intervene or influence <U>your</U>
operations&rdquo; to instead state that the PRC government may at any time or influence &ldquo;<U>our</U>&rdquo; operations, to communicate
that you are discussing the operations of the company (emphasis added).</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>Revise your disclosure that the PRC government &ldquo;may exert more control through regulation revisions
or interpretation implementation&rdquo; to clarify that they may exert more control <U>over offerings conducted overseas and/or foreign
investment in China-based issuers</U> (emphasis added).</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in">&#9679;</TD><TD STYLE="text-align: justify"><B>We note your disclosure that &ldquo;[i]f that happens, it may completely hinder our ability to offer
or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.&rdquo; Also
state that such actions could result in a material change in your operations and/or the value of the securities being offered.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has revised its disclosure accordingly as requested under the section titled &ldquo;<I>Cautionary Statement
Regarding Doing Business in China&rdquo;</I> in the Amended F-3. In addition, the Company has added a summary of risk factors which includes
cross-references to the relevant individual detailed risk factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Enforceability of Civil Liabilities, page
46</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>20.</B></TD><TD STYLE="text-align: justify"><B>We note your disclosure that &ldquo;a majority of our directors and officers are nationals or residents
of jurisdictions other than the United States.&rdquo; To the extent that you have one or more directors, officers or members of senior
management located in the PRC/Hong Kong, please revise to state that is the case and identify the relevant individuals here. Please also
include a separate risk factor addressing the challenges of bringing actions and enforcing judgments/liabilities against such individuals.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, the Company has identified the relevant individuals under such Section and also has added a separate risk factor
entitled &ldquo;<I>You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions
in China against us or our management named in the prospectus based on foreign laws&rdquo;</I> as requested in the Risk Factors of the
Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Exhibit 5.1, page II-1 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>21.</B></TD><TD STYLE="text-align: justify"><B>Please delete as inappropriate the statement that the &ldquo;opinion is issued solely for your benefit
and use in connection with the matter described herein and is not to be relied upon by any other person, firm or entity . . . .&rdquo;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"><B>Response:
</B>In response to the Staff&rsquo;s comment, the Cayman counsel has made revisions to one of its qualifications and updated opinion letter
with such revisions is filed as Exhibit 5.1 to the Amended F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B><U>General</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.5in"><B>22.</B></TD><TD STYLE="text-align: justify"><B>Please file an updated consent from BDO China Shu Lun Pan Certified Public Accountants
LLP regarding their reports dated June 29, 2021, related to the consolidated financial statements for the fiscal year ended March 31,
2021.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><B>Response: </B>In response to
the Staff&rsquo;s comment, the Company has filed an updated consent from BDO China Shu Lun Pan Certified Public Accountants LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We thank the Staff
for your review of the foregoing. If you have any questions, please do not hesitate to contact the undersigned at frank.zhao@jojodrugstores.com,
or Elizabeth Fei Chen of Pryor Cashman LLP, the outside counsel to the Company, at echen@pryorcashman.com (Tel: 212-326-0199).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 35%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Ming Zhao </FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Ming Zhao</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-bottom: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">cc:&nbsp;</FONT></TD>
    <TD STYLE="width: 97%; padding-bottom: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Elizabeth Fei Chen, Esq.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.05in; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
